Regulator Approves Pershing Square Allergan Buy

May 5 2014 | 11:32am ET

Pershing Square Capital Management has already made $1.2 billion on its huge stake in Allergan Inc., one which it has now won the green light to finalize.

The New York-based hedge fund built its 9.7% stake in the Botox maker primarily with call options and forward purchase contracts. Federal law requires investors to notify both the Federal Trade Commission and Justice Department about plans to buy voting securities; Pershing Square did so on April 21, and won permission from the FTC last week.

There is normally a 30-day waiting period for such acquiescence; Pershing Square got it within two weeks.

Pershing Square is working with Valeant Pharmaceuticals International on the Allergan deal. Valeant has proposed a $46 billion hostile takeover of Allergan, which Pershing Square supports. Allergan is Pershing Square’s largest-ever investment, and buying the shares it has the right to would take about one-third of its assets under management.

At the moment, the investment is also one of Pershing Square’s most successful: The stock is trading about 34% higher than the hedge fund’s average price. In addition, other hedge funds have leapt into the fray, with Citadel Investment Group, Highfields Capital and Viking Global Investors all buying Allergan stakes recently.


In Depth

Q&A: Reg A+ Will Transform the Alternative Asset Landscape

Jul 7 2015 | 4:03pm ET

In addition to easing capital formation for small companies, Regulation A+ has enormous...

Lifestyle

Fiat Chrysler Files Paperwork For Ferrari IPO

Jul 23 2015 | 5:05pm ET

Italian sportscar maker Ferrari has taken a step closer to a stock market listing...

Guest Contributor

Lifting of Foreign Ownership Limits Signals Sea Change in Vietnam's Capital Markets

Jul 28 2015 | 3:01pm ET

The lifting of restrictions on foreign ownership limits in Vietnam later this year...

 

Editor's Note